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Abstract
Purpose. There are, in general, few published series on chordoma. It is a rare disease and further data are still needed.
Patients The data of 37 patients with chordoma were retrospectively analyzed. Treatment was surgical excision
in 11, radical radiotherapy in 9 and a combination of the two in 16 cases. The male to female ratio was 2.7"1. Median
age was 59 years (range 1-89 years).
Results. The most common symptoms at diagnosis were pain (98%), neurological disturbances (42%) and incontinence
(33%). The tumours were located in the sacro-coccygeal region in 68%, the spheno-occipital region in 16% and the
vertebrae in 16% of the patients. Median tumour.size was 7 cm (range 1-30 cm). Local recurrence occurred in 21/36
treated cases and distant metastases developed in eight patients (23%). The median time to recurrence/progression after
primary treatment was 2 years (range 1-10 years). The actuarial 5-year rates of overall, progression-free and symptom-free
survival were 40%, 31% and 20%, respectively. The corresponding 10-year rates were 26%, 21% and 14%, respectively.
At the time of analysis, seven patients were alive, six without evidence of disease. Four of the six patients without active
disease were symptom free. A univariate analysis showed that age, sex, tumour size, histopathology, surgical safety margin,
treatment modality and radiation dose did not significantly affect overall, progression-free or symptom-free survival. Only
turnout site had a prognostic value with turnouts in the spheno-occipital region carrying the worst prognosis.
Discussion. We conclude that effective treatment against chordomas is still lacking and a prospective multi-institutional
registration study may provide more information on the optimal work-up and treatment of this rare disease.
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Introduction
Chordomas are rare turnouts that arise along the
axial skeleton with the sacro-coccygeal and the
spheno-occipital regions being the two most
favoured sites. 1’2 They are generally considered to
arise from remnants of notochordal tissue.
3 Surgery
and radiation therapy are the main lines of treat-
ment. However, the close proximity of these
turnouts to critical neural and skeletal tissues can
compromise both the radical approach of surgical
resection and radiation dose. Radiotherapy is usu-
ally recommended in inoperable cases, following
surgery, or for the treatment of gross recurrence.4
The timing of radiotherapy and the optimum radi-
ation dose and fractionation have not been estab-
lished. Local control is poor and death is most
often caused by consequences of uncontrolled local
tumour growth.
6 Distant metastases are not uncom-
mon but their frequency varies widely between pub-
lished series. 1’7 No chemotherapeutic regimen has
been shown to be effective against these tumours. 4’8
In general, there are few published series on chor-
doma, and because of the rarity of the disease few
publications contain more than 25 patients. No
prospective randomized studies have been reported.
Hence, in most cases, the available data in the
literature represent selected patients. This may
explain partially the discrepancies between results,
and more clinical reports are therefore still needed.
This paper represents the first published description
of the Danish experience in the management of
patients with chordoma.
Patients and methods
This national Danish study of 37 patients represents
all the patients treated in the three major sarcoma
centres in Denmark in the last 25 years. The files of
all patients were reviewed and all histopathological
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specimens were reviewed centrally by one of the
authors (OM-J).
Primary treatment was surgical resection in 11
patients, radical radiotherapy in 9 patients and com-
bined surgical excision and post-operative radiother-
apy in 16 patients. One patient did not receive any
treatment after tumour biopsy. It was not clear in
the file why this was so. The major goal of surgery
was total turnout removal, but such surgery was
only considered feasible in four patients with chor-
domas in the sacro-coccygeal region. Over this long
study period the operative approaches varied
according to both the location of the tumour and
the experience of the surgeons. Chemotherapy was
not given as part of the primary treatment. One
patient was lost to follow-up. The median time of
follow-up was 62 months (range 4-236 months).
The therapeutic results were evaluated in terms of
symptomatic relief, local control and survival. Over-
all survival, progression-free survival and symptom-
free survival were calculated using the actuarial
approach,
9 and differences were tested by the log-
rank test.1 The log-rank test was used as a univari-
ate analysis of actuarial estimates in an attempt to
elucidate the role of various possible prognostic
factors. These factors included: age, sex, tumour
size, tumour site, surgical safety margin, treatment
modality and radiation dose.
Results
Natural history
In Denmark, between one and five chordomas are
diagnosed per year. In the present series, there were
27 males and 10 females, i.e. the male to female
ratio was 2.7"1. The age of patients ranged from 1
to 89 years with a median age of 59 years. Median
duration of symptoms before admission was 12
months (range 1-84 months). Symptoms dominat-
ing at diagnosis were pain (98%), neurological dis-
turbances (42%) and incontinence (33%).
The tumours were located in the sacro-coccygeal
region in 25 patients (68%), spheno-occipital region
in six patients (16%) and vertebrae in six patients
(16%). The median value of ’maximum tumour
diameter’ was estimated to be 7 cm (range 1-
30 cm), with the large tumours mainly seen at the
sacral region; however, it should be noted that the
methods used to measure turnout size varied from
simple clinical judgement to measurements based
on magnetic resonance scanning.
Treatment results
Of the 27 patients in whom an attempt at surgical
excision was part of their initial treatment, a wide
safety margin could be achieved in only four cases (all
sacral). Surgery was intra-lesional in 17 cases and
marginal in six cases. After the initial primary surgery,
only the four patients with wide safety margins were
evaluated as being in complete remission.
Radiotherapy was given with conventional fraction-
ation (1.8-2.5 Gy/fraction, 5 fractions/week) in 15
patients. High dose per fraction (3-4 Gy/fraction) was
used in four patients and multiple fractions per day
with small dose per fraction (1-1.7 Gy/fraction) in
five patients. In one patient the fractionation schedule
was not reported. The median total radiation dose
was 55 Gy (range 30-80 Gy) and the median number
of fractions 29 (range 13-50 fractions). In the group
treated with radiation alone the median dose was
57 Gy and the median number of fractions 24, and in
the group treated with combined surgery and radi-
ation the median dose was 55 Gy and the median
number of fractions 30.
The time to recurrence (local or distant) following
primary treatment ranged from 1 to 10 years with a
median of 2 years. The one patient who did not
receive any primary treatment after biopsy had pro-
gression of his local disease 14 years after diagnosis.
This was eventually the cause of his death. Local
recurrence was defined as pathological or radiologi-
cal evidence of disease progression occurring more
than 6 months after treatment. Local recurrence
occurred in 21/36 treated patients (58%). Distant
metastases developed in 8/36 treated patients
(23%). In 5/8 cases, metastases were not
accompanied by local disease.
Treatment of local recurrence was surgical in four
cases, radiotherapy in three cases and surgery plus
post-operative radiotherapy in six cases. In eight
cases, no treatment was given, mainly because ofpoor
general condition or inoperability. Chemotherapy was
given to 3/8 metastatic cases, and the regimens used
were single-drug doxorubicin, single-drug ifosfamide
and CYVADIC (cyclophosphamide, vincristine,
doxorubicin, dacarbazine), respectively. The time
from recurrence to death ranged from 0 to 84 months
with a median of 15 months. However, the median
time from the diagnosis of progression to death was
26.5 months (range 5-84 months) for the treated
group and 14.5 months (range 4-28 months) for the
untreated group.
At the time of analysis, seven patients were alive,
six without active disease. Four of the six patients
alive without active disease were symptom free.
Progression of disease was the cause of death in 18
patients. In three patients with active disease, death
was due to other, unrelated, diseases. In three
patients with active disease, death was directly
attributed to treatment complications. One patient
with a chordoma in the spheno-occipital region died
8 days after surgery probably due to cerebral
oedema, one died of an osteosarcoma probably sec-
ondary to the irradiation, and one died of gas-
trointestinal complications probably related to the
irradiation. In four patients the cause of death was
not defined and only one patient died from an
unrelated cause while in complete remission.lOO
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Fig. 1. Acturial (Kaplan-Meier) estimate of overall sur-
vival, progression-free survivalandsymptom-free survivalfor all
patients over an extended period offollow-up.
The actuarial 5-year rates of overall, progression-
free and symptom-free survival (_ 1 SE) were 40%
(___9%), 31% (_8%) and 20% (___7%), respect-
ively. The corresponding 10-year rates were 26%
(+__8%),21% (___7%) and 14% (_6%) for overall,
progression-free and symptom-free survival, respect-
ively (Fig. 1).
Prognostic facwrs
As seen in Table 1, the outcome of therapy (5-year
overall, progression-free and symptom-free survival)
did not differ between the various treatment groups.
Table 2 shows that with the exception of tumour
site, none of the prognostic factors studied was
found to affect survival, progression-free survival or
symptom-free survival. Continuous variables (age,
tumour size and radiation dose) were divided into
two at the median values. To compensate for the
variation in fractionation schedules the total dose
was calculated in terms of biological effective dose
(BED) using the equation:
BED nd (1 + d//[3)
where n number of fractions, d dose per fraction
and ,/ for chordoma was estimated to be 7 Gy.
Still, no effect of BED was found on survival, pro-
gression-free survival and symptom-free survival.
Patients with chordomas of the spheno-occipital
region did much worse than patients with chordo-
mas in any other site. None of the patients with
spheno-occipital tumours survived for 5 years. This
difference in survival was statistically significant
(p 0.001), while there was no difference in survival
between vertebral and sacral chordomas (Fig. 2).
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Discussion
Because of the rarity of the disease, this series of 37
patients is actually one of the largest in the pub-
lished literature. The natural history and clinico-
pathological criteria of the chordoma reported in
this study agree with most of the reported figures.
These include the median age of 59 years1’11’12 and
a male to female ratio of around 2"17’12 Chordomas
are known to have a slow rate of progression. The
duration of symptoms before diagnosis is therefore
relatively long’11 and agrees perfectly with the
median duration of 12 months reported here.
Spheno-occipital chordomas represented 16%
of our cases. This value is lower than the
35-68% incidence reported frequently in the litera-
ture. 1,5,13
Until recently, sex was not thought to be of
prognostic value in chordomas.’60’Connell et al.,
4
however, suggested that female sex was an indepen-
dent predictor of shortened survival in base of skull
chordomas. The same observation was reported by
15 Thieblemont et al., in a study of 26 cases of
chordomas in various sites. They defined a favour-
able group of males younger than 60 years, and an
unfavourable group of females and males older than
60 years. We were unable to reproduce this observa-
tion in our study. Given the small number of
patients in their study, the prognostic value of com-
bined gender and age reported by Thieblemont et al.
still has to be confirmed by other studies. Although
not generally accepted, some studies have reported a
trend for patients over 40 years of age to have a
worse prognosis,
4 especially with base of skull chor-
domas. 16 In the present study, age did not have an
effect on survival.
O’Connell et al. have found that patients with
base of skull chordomas larger than 70 ml have a
significantly worse survival than those with smaller
tumours.
14 Although intuitively obvious, the study
4
was the first to demonstrate that quantitative vol-
ume measurement may have prognostic
significance. In our study, tumour size was
not correlated with survival or progression-free sur-
vival. In contrast to the study by O’Connell et al.
we reported chordomas in various sites. The effect
of tumour size could have been concealed by the
fact that large tumours were located in the sacro-
coccygeal region, a site amenable to a more radical
surgical excision than the base of the skull. Saxton
classified his patients according to tumour size
(tumours < 4 cm or > 4 cm diameter) and found no
difference in outcome.
17 It should be noted, how-
ever, that while computed tomography or magnetic
resonance scanning were routinely used to estimate
tumour size beginning in the late 1970s, various
other methods were adopted to estimate tumour size
from X-rays in the earlier days. Therefore, the
reported median tumour sizes can only be regarded
as an approximation.164 A. Safwat et al.
Table 1.
Treatment
The 5-year survival results of chordoma patients according to treatment
modality
Overall Progression- Symptom-free
Number of survival free survival survival
patients (%) (%) (%)
Radiation 9 41 34 30
Surgery 11 33 30 17
Combined 16 50 33 27
Table 2. The results of a univariate analysis (og-rank test) on the
influence of various variables on survival, progression-free survival and
symptom-free survival in patients with chordomas
Overall Progression- Symptom-
Variable survival free survival free survival
Age (60 years) NS NS NS
Tumour size (7 cm) NS NS NS
Tumour site 0.0017 NS NS
Sex NS NS NS
Surgical margin NS NS NS
Dose (75 Gy BED) NS NS NS
Treatment modality NS NS NS
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Fig. 2. Actuarial (Kaplan-Meier) estimate of overall sur-
vivalfor chordoma patients according to site of tumor.
Pathological features such as ploidy were reported
to show a statistical trend for prognostic significance
in chordoma patients.
3 Also, chondroid chordoma
subtype is known to carry a better prognosis.
16 None
of the cases reported here was described as chon-
droid chordoma. The metastasis rate of 23% re-
ported here confirms the potential metastatic nature
of chordomas stated in most of the recent litera-
ture. 1,4-6
The factors that can affect radiation response
such as total dose, radiation quality and technique
varied significantly in this small cohort of patients.
This may explain the absence of any correlation
between the radiation parameters and any of the
studied endpoints. To compensate for the variation
in fractionation schedules the total dose was calcu-
lated in terms of BED. The // ratio of 7 Gy for
chordoma was chosen arbitrarily. The same value
was used previously by Tai et al. who also failed to
demonstrate a dose-response relationship.
18 Chang-
ing the //3 ratio value did not change the overall
results.
Treatment of recurrence had a life-prolonging
effect as seen by the longer median survival in the
treated groups. Treatment options were limited,
however, by practical problems such as operability
and the initial radiation dose.
The survival and progression-free survival figures
reported here are similar to those reported in the
literature. 1’4-6 Despite advances in surgical tech-
niques and the technology of radiotherapy, these
figures have not changed much in the last 25 years.
It is important to emphasize that even after a long
survival time, late recurrences can occur and few of
the patients alive would be without active disease.
More disturbing is the fact that even fewer patients
are actually symptom free.
None of our patients with spheno-occipital chor-
domas survived for 5 years. This could be explained
in part by the absence of chondroid chondromas in
this series, the favourable histological subtype in this
material. These poor survival results illustrate the
limited ability of conventional treatments for chor-
domas of the base of the skull. A recent study using
charged heavy particle beam radiotherapy reported a
5-year local control rate of 580/0.19We conclude that effective treatments for chordo-
mas are still lacking. Although a group of patients
may be long-term survivors, very few are symptom-
free and in general the prognosis is rather poor. A
multi-institutional prospective registration study
may provide more information on the optimal work-
up and treatment of this rare disease.
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